Pirfenidone CAS 53179-13-8 Purity ≥99.0% (HPLC) IPF
Shanghai Ruifu Chemical is the leading manufacturer of Pirfenidone (CAS: 53179-13-8) with high quality, for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Pirfenidone, Please contact: alvin@ruifuchem.com
| Chemical Name | Pirfenidone |
| Synonyms | Perfenidone; 5-Methyl-1-Phenylpyridine-2(1H)-one; 5-Methyl-1-Phenylpyridin-2-one; 5-Methyl-1-Phenyl-2-Pyridone; PFD; S-7701; AMR-69 |
| CAS Number | 53179-13-8 |
| Stock Status | In Stock, Production Capacity 1000kg per Month |
| Molecular Formula | C12H11NO |
| Molecular Weight | 185.22 |
| Melting Point | 102.0~109.0℃ |
| Density | 1.137±0.06 g/cm3 |
| Solubility | Soluble in DMSO |
| COA & MSDS | Available |
| Origin of Product | Shanghai, China |
| Product Categories | API (Active Pharmaceutical Ingredient) |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Light Yellow Crystalline Powder |
| Identification | IR |
| Pirfenidone Purity | ≥99.0% (HPLC) |
| Melting Point | 102.0~109.0℃ |
| Loss on Drying | ≤0.50% |
| Sulfated Ash | ≤0.20% |
| Single Impurity | ≤0.50% |
| Total Impurities | ≤1.00% |
| Heavy Metals | ≤20ppm |
| Test Standard | Enterprise Standard |
| Usage | API, Idiopathic Pulmonary Fibrosis (IPF) |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.
Hazard Symbols Xn - Harmful
Risk Codes 22 - Harmful if swallowed
Safety Description S36 - Wear suitable protective clothing.
S24/25 - Avoid contact with skin and eyes.
WGK Germany 3
RTECS UV1148200
HS Code 2933 3990.99
Pirfenidone (CAS: 53179-13-8) is in a group of medicines called antifibrotic agents. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. It affects your body’s immune system and reduces the amount of fibrosis (scarring) in the lungs. Pirfenidone is one of two medicines that are approved in Canada to treat Idiopathic Pulmonary Fibrosis (IPF). Pirfenidone is an inhibitor for TGF-β production and TGF-β stimulated collagen production, reduces production of TNF-α and IL-1β, and also has anti-fibrotic and anti-inflammatory properties. It was first approved in Japan for the treatment of patients with idiopathic pulmonary fibrosis after clinical trials, under the trade name of Pirespa by Shionogi, in 2008. It was approved for use in the European Union in 2011, in Canada in 2012, and in the United States in October 2014.
